逍遥散联合氟西汀治疗冠心病伴抑郁症60例

Xiaoyaosan Combined with Flouxetine in the Treatment of Coronary Heart Disease Associated with Depression for 60 Cases

目的探讨逍遥散加味联合氟西汀盐酸盐(百忧解)分散片治疗冠心病伴抑郁症的临床疗效。方法将120例冠心病伴抑郁症患者随机分为对照组和治疗组各60例。两组均给予常规方法治疗冠心病(如阿斯匹林、硝酸酯类药物、钙离子拮抗剂、β受体阻滞剂、他汀类药物等),对照组给予氟西汀治疗,治疗组在对照组的基础上加用逍遥散加味治疗。两组均治疗8周后进行疗效临床指标观察。结果在治疗8周后,治疗组的HAMD抑郁量表评分均显著低于对照组,差异有统计学意义(P<0.05);治疗8周后,心绞痛症状改善总有效率为90.0%,对照组为76.7%。两组比较,差异有统计学意义(P<0.05);不良反应发生率治疗组为6.7%,对照组为16.6%,差异具有统计学意义(P<0.05)。结论逍遥散加味联合氟西汀治疗冠心病伴抑郁症疗效显著,不良反应少。

Objective To investigate the efficiency of modified Xiaoyaosan combined with Flouxetine for the treatment of clinical coronary heart disease associated with depression. Methods 120 cases of coronary heart disease associated with depression patients were randomly divided into two groups, 60 cases in each group. Two groups were given conventional treatment of coronary heart disease （such as aspirin, nitrates, calcium antagonists, beta blockers, statins, etc.） . The patients in the control group were treated with Flouxetine; the patients in the observation group were treated with modified Xiaoyaosan combined with Flouxetine. Analyze the clinical efficacy of the two treatments after 8 weeks. Results 8 weeks later, HAMD depression scale score of the treatment group were significantly lower than that of the con-trol group, the difference was statistically significant （ P〈0.05） ; the total effective rate of angina symptoms improvement was 90.0%, and was76.7% for the control group, the difference was statistically significant （ P〈0.05） . Incidence of adverse reactions in the treatment group was 6.7%, and was 16.6% for the control group, the difference was statistically significant （ P〈0.05） . Conclusion Modified Xi-aoyaosan combined with Flouxetine in the treatment of clinical coronary heart disease associated with depression was efficient and had less adverse reaction.